
Opinion|Videos|September 11, 2024
Understanding Oligometastatic Disease in Prostate Cancer: Insights from PSMA PET Imaging
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD 
Key opinion leaders examine the role of advanced imaging agents, particularly PSMA PET and other radiotracers, in identifying and defining oligometastatic disease in patients with prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do imaging agents, such as PSMA PET or other radiotracers, contribute to the detection and characterization of oligometastasis in prostate cancer patients?
 
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Can Ultrasound-Derived Fat Fraction Provide a Viable Alternative for Quantifying Hepatic Steatosis?
2
FDA Grants De Novo Approval for Home Use of Prenatal Ultrasound Platform
3
‘How Did That Happen?’: Course Correction Versus Consternation in Radiology
4





























